Human medicines European public assessment report (EPAR): Kisqali, ribociclib, Breast Neoplasms, Date of authorisation: 22/08/2017, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Spectrila, asparaginase, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Date of authorisation: 14/01/2016, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Obizur, susoctocog alfa, Hemophilia A, Date of authorisation: 11/11/2015, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Multiple Sclerosis, Date of authorisation: 27/06/2006, Revision: 41, Status: Authorised

Human medicines European public assessment report (EPAR): Nordimet, methotrexate, Arthritis, Psoriatic;Psoriasis;Arthritis, Juvenile Rheumatoid;Arthritis, Rheumatoid, Date of authorisation: 18/08/2016, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Pegasys, peginterferon alfa-2a, Hepatitis C, Chronic;Hepatitis B, Chronic, Date of authorisation: 20/06/2002, Revision: 46, Status: Authorised

Human medicines European public assessment report (EPAR): Ozurdex, dexamethasone, Macular Edema;Uveitis, Date of authorisation: 26/07/2010, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Vimizim, elosulfase alfa, Mucopolysaccharidosis IV, Date of authorisation: 27/04/2014, Revision: 13, Status: Authorised

Strengthening life-sciences innovation across Europe: EU-Innovation Network conference, Dublin and online (hybrid), from 21/11/2023 to 21/11/2023

Human medicines European public assessment report (EPAR): Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan, efavirenz,emtricitabine,tenofovir disoproxil, HIV Infections, Date of authorisation: 05/09/2017, Revision: 16, Status: Authorised